Checked
Anaptysbio, Inc
Nasdaq: ANAB · Pharmaceutical Preparations · San Diego, CA
- Revenue
- $234.6M
- +157.0% vs. prior year
- Net income
- -$13.23M
- -5.6% net margin
- Total assets
- $364.4M
- Diluted EPS
- -$0.44
Company details
As reported to the SEC
- SEC CIK
- 1370053
- Stock
- Nasdaq: ANAB
- Legal Entity Identifier (LEI)
- 529900HH4WQT03IG1A12
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 10770 Wateridge Circle, Suite 210, San Diego, CA 92121
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- June 30
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (858) 362-6295
- Employer ID (EIN)
- 20-3828755
- Last annual report
- 09/21/2026
- Last quarterly report
- 05/12/2026
Formerly: ANAPTYSBIO INC (until 06/12/2019); ANAPTYS BIOSCIENCES INC (until 11/20/2007)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.28M | $17.16M | $10.29M | $63.17M |
| Operating income | $226.9M | $66.15M | -$164.4M | -$115.2M | -$56.81M |
| Net income | -$13.23M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| Diluted earnings per share | -$0.44 | -$4.92 | -$6.08 | -$4.57 | -$2.11 |
| Research and development | $136M | $163.8M | $132.3M | $88.8M | $98.5M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Shareholders' equity | $37.21M | $70.87M | $88.1M | $262.1M | $356.4M |
| Cash and cash equivalents | $138.2M | $23.08M | $35.97M | $71.31M | $495.7M |
| Cash from operations | $19.7M | -$135.3M | -$120.8M | -$73.59M | -$45.92M |
| Capital expenditures | $87K | $358K | $807K | $358K | $1.37M |
Recent filings
123 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
100 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Anaptysbio, Inc in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Anaptysbio, Inc's CIK number?
- Anaptysbio, Inc's SEC Central Index Key (CIK) is 1370053.
- What is Anaptysbio, Inc's stock ticker?
- Anaptysbio, Inc trades as Nasdaq: ANAB.
- What was Anaptysbio, Inc's revenue?
- Anaptysbio, Inc reported revenue of $234.6M for the fiscal year ended Dec 31, 2025, +157.0% from the year before.
- When does Anaptysbio, Inc's fiscal year end?
- Anaptysbio, Inc's fiscal year end on file with the SEC is June 30; its most recent fiscal year ended Dec 31, 2025.
- Where is Anaptysbio, Inc headquartered?
- Anaptysbio, Inc's principal executive office on file with the SEC is in San Diego, CA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026